MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Nested ANCOVA models including a treatment × imaging measure interaction were compared using partial F-tests to assess whether the effect of ExQW treatment differed by severity of hypothalamic damage.

Who Took Part

Subjects underwent MRI prior to enrolment and the degree of hypothalamic damage was assessed using an integrative hypothalamic lesion score (HLS).

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Exenatide, giving a reference point.

More than one site took part, so the participants came from several places.

Mammillary body (MB) damage was specifically determined.

The main clinical endpoints were % change in body mass index (BMI) and change in % body fat.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Magnetic Resonance Imaging and Obesity.

The authors tagged it with the keywords GLP-1 analogue, body composition, clinical trial and obesity therapy.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Exenatide compound page, all human trials.